1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  12:08 2022-08-18 am EDT
3841.00 JPY   -0.98%
08/15CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tablet
PU
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
AQ
08/10Roche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2022

02/03/2022 | 03:00am EDT

Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2022. For the period, the company expects revenues of ¥1,150,000 million, Core operating profit of ¥440,000 million, Core net income of ¥312,500 million and Core earnings per share of ¥190.00.


© S&P Capital IQ 2022
All news about CHUGAI PHARMACEUTICAL CO., LTD
08/15CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tabl..
PU
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priorit..
AQ
08/10Roche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
08/10CHUGAI PHARMACEUTICAL : Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in C..
PU
08/09Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig..
AQ
08/08Chugai Pharmaceutical Co., Ltd. - Maruho Launched in Japan the Anti-IL-31 Receptor a Hu..
AQ
08/08CHUGAI PHARMACEUTICAL : Notice of the Settlement of Patent Infringement Litigation in the ..
PU
08/08Roche's Chugai Unit Launches Skin Disease Drug in Japan
MT
08/07CHUGAI PHARMACEUTICAL : Maruho Launched in Japan the Anti-IL-31 Receptor A Humanized Monoc..
PU
07/27Nikkei 225 Up 0.2% Ahead of Federal Reserve Announcement
MT
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2022 1 191 B 8 801 M 8 801 M
Net income 2022 347 B 2 565 M 2 565 M
Net cash 2022 518 B 3 829 M 3 829 M
P/E ratio 2022 18,4x
Yield 2022 2,05%
Capitalization 6 381 B 47 141 M 47 141 M
EV / Sales 2022 4,92x
EV / Sales 2023 5,40x
Nbr of Employees 7 664
Free-Float 38,0%
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 3 879,00 JPY
Average target price 4 617,50 JPY
Spread / Average Target 19,0%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD3.48%47 349
JOHNSON & JOHNSON-2.04%440 572
ELI LILLY AND COMPANY14.70%294 849
PFIZER, INC.-16.56%279 832
ROCHE HOLDING AG-16.74%273 886
ABBVIE INC.4.46%252 042